Cited 21 times in
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.